EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide ‐1‐based therapy

Satya Dash iD

Diabetes, Obesity and Metabolism · 2024-09 · 26 (S4) · 3-15

DOI: 10.1111/dom.15829 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 19.08.2024. Verfasst von Satya Dash. Beteiligte Einrichtung: Division of Endocrinology, University Health Network & University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Obesity, Weight Loss. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a chronic multi‐system disease and major driver of type 2 diabetes and cardiometabolic disease. Nutritional interventions form the cornerstone of obesity and type 2 diabetes management. Some interventions such as Mediterranean diet can reduce incident cardiovascular disease, probably independently of weight loss. Weight loss of 5% or greater can improve many adiposity‐related comorbidities. Although this can be achieved with lifestyle intervention, it is often difficult to sustain in the longer term due to adaptive endocrine changes. In recent years glucagon‐like‐peptide‐1 receptor agonists (GLP‐1RAs) have emerged as effective treatments for both type 2 diabetes and obesity. Newer GLP‐1RAs can achieve average weight loss of 15% or greater and improve cardiometabolic health. There is heterogeneity in the weight loss response to GLP‐1RAs, with a substantial number of patients unable to achieve 5% or greater weight. Weight loss, on average, is lower in older adults, male patients and people with type 2 diabetes. Mechanistic studies are needed to understand the aetiology of this variable response. Gastrointestinal side effects leading to medication discontinuation are a concern with GLP‐1RA treatment, based on real‐world data. With weight loss of 20% or higher with newer GLP‐1RAs, nutritional deficiency and sarcopenia are also potential concerns. Lifestyle interventions that may potentially mitigate the side effects of GLP‐1RA treatment and enhance weight loss are discussed here. The efficacy of such interventions awaits confirmation with well‐designed randomized controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1ObesityWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsLife StyleCombined Modality TherapyMaleFemale

Stichwörter der Autor:innen

GLP‐1 analoguedietary interventionincretin therapyweight control

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Endocrinology, University Health Network & University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada.

ORCID-Profile: Satya Dash

Zitieren

APA

Dash, S. (2024). Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide ‐1‐based therapy. Diabetes, Obesity and Metabolism, 26(S4), 3-15. https://doi.org/10.1111/dom.15829

Vancouver

Dash S. Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide ‐1‐based therapy. Diabetes, Obesity and Metabolism. 2024;26(S4):3-15. doi:10.1111/dom.15829

BibTeX
@article{Dash2024,
  author = {Dash, Satya},
  title = {Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide ‐1‐based therapy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {S4},
  pages = {3--15},
  doi = {10.1111/dom.15829}
}
Kostenlos starten →